We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Morgan Goodwin is a UK-based company that pioneers the Combined Trading Platform (CTP) category, offering a comprehensive online platform for small businesses engaged in physical goods trading, along with specialized software development services, and a broad-spectrum business consultancy approach aimed at enhancing growth, efficiency, and technological advancement.
days to go: Stretch investment: £788,519
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Doqit offers a solution for managing life admin tasks, helping you organize important information, set action dates, and receive timely reminders, ultimately streamlining tasks like insurance renewals and warranties to reduce unnecessary expenses and simplify your life. It provides secure storage and easy access for vital information, transitioning from chaos to simplicity.  Security is also a priority for Doqit. The platform ensures that your sensitive information is stored securely, giving you peace of mind knowing that you can access your important documents and data whenever you need them, all within a few clicks.
days to go: Extended investment: £87,500
UTU is a company dedicated to building the trust infrastructure for the evolving web 3.0. They aim to facilitate safer and more reliable interactions between users and platforms by utilizing a decentralized reputation and reviews protocol. This protocol involves a non-tradable reputation token (UTT) that users can stake to endorse others, leading to positive outcomes. UTU's focus initially lies in Web3 and DeFi apps, where they provide AI-powered tools to curate trust signals and help users engage confidently in various online activities. They offer a range of products, including the UTU Trust Token, Browser Extension, and Trust API/SDK, all aimed at enhancing trust and security in digital interactions.
days to go: Extended investment: £150,000
Wi-Fi Securities Limited is a cyber security company that aims to revolutionise the security of public access Wi-Fi. To realise this vision, the company is developing a unique patent-protected system called SpriteGuard™ which will protect you and your data from hackers by stopping you connecting to fake hotspots. The system is targeted towards the $550 bn worldwide hospitality industry and has the ability to expand to other large global markets like city-wide free Wi-Fi, airports and coffee shops. Moreover, Wi-Fi Securities Limited has a highly experienced Wi-Fi Securities management board that has a track record of delivering multi-million-pound projects from concept to successful commercial deployment.

Pitch Rated

77%

Overall

rating powered by

CROWD RATING™

days to go: Extended investment: £1,014,708
Balkerne is designing a commercial insurance product based on Risk Management technology and Property & Casualty Insurance. Through this way, the company helps enterprises defend their property and people. The company will make sure that no property owner suffers from theft, fire or flood. It has generated net revenue of £21K in January 2019. The revenue model of Balkerne is to charge a percentage of the premium to distribute insurance and support customers with risk management by managing claims. The company has come up with an exit strategy that is to improve the performance of the acquiring company and to quickly acquire the skills and technologies at a lower cost.
days to go: Expired investment: £150,000
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.

Pitch Rated

50%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £215,946
Muniy makes banking easy for everyone, spreading a digital banking revolution with a focus on improving user experience, not only for familiar banking functions, but extending into other areas, such as retail experience, where people spend money. With Muniy's recently launched personal mobile money application as well as Muniy contactless card in the UK and Europe, the company aims to be at the forefront of banking innovation. The application can be used to pay via QR code, Mastercard, or for P2P transactions. By paying with Muniy, customers connect with merchants anonymously allowing the latter to profit from lower transaction processing costs. The company aims to introduce personalised rewards to its customers and soon launch the application in the Middle East. The company will utilise the investments to run a pilot in the UK and the European Union is a political and economic union of 27 member, and leverage a mature market to establish a foundation quickly in order to introduce their core financial services to key markets in the Middle East.

Pitch Rated

43%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £207,510
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph